Clinical trial
A Prospective, Single-arm, Phase II Study of Neoadjuvant Sacituzumab Tirumotecan (SKB264/MK-2870) Combined With Toripalimab in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
NCT07823270 is registered in ClinicalTrials.gov with Hebei Medical University Fourth Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Single-arm, Phase II Study of Neoadjuvant Sacituzumab Tirumotecan (SKB264/MK-2870) Combined With Toripalimab in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
- Lead sponsor
- Hebei Medical University Fourth Hospital
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- October 31, 2026
- Completion date
- December 31, 2030
- Enrollment
- 33 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.